KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

This study is testing a new combination treatment for advanced esophageal cancer (cancer of the food pipe) that has returned or spread. The treatment combines a new drug called KC1036 with an immune therapy drug (PD-1 antibody) and standard platinum-based chemotherapy — all given together as a first-line treatment. **You may be eligible if...** - You are aged 18–75 with a confirmed diagnosis of esophageal squamous cell carcinoma that is advanced or has spread - You have not yet received any systemic treatment for your current cancer - You have at least one measurable tumor and are in good physical condition (ECOG 0–1) - Your bone marrow, kidney, and liver are functioning adequately - Your life expectancy is more than 12 weeks **You may NOT be eligible if...** - Your cancer has spread to the brain and is causing symptoms - You have had another cancer in the past 5 years - You have received prior immunotherapy or anti-angiogenic drugs - You have serious heart, kidney, or gastrointestinal problems - You have an active autoimmune disease or serious infection - You are pregnant or breastfeeding - You have a tumor that is close to major blood vessels or airways, creating a bleeding or fistula risk Talk to your doctor to see if this trial is right for you.